Sep 30, 2020
Autor: Antônio Carlos Pires
Ref: The Primary Glucose-Lowering Effect of Metformin Resides in
the Gut, Not the Circulation: Results From Short-term
Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes
Care. 2016 Feb;39(2):198-205
Sep 30, 2020
Autor: Alexander Benchimol
Ref: Empagliflozin and Progression of Kidney Disease in Type 2
Diabetes. N Engl J Med. 2016 Jul
28;375(4):323-34
Sep 30, 2020
Autor: Fernando Valente
Ref: Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? No, We Should Never Again Compromise Safety! Diabetes Care. 2016 Jul;39(7):1281-6.
e
Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?
Sep 25, 2020
Autora: Fani Eta Korn Malerbi
Ref: HypoAware: development and pilot study of a brief and partly web-based psychoeducational group intervention for adults with Type 1 and insulin-treated Type 2 diabetes and problematic hypoglycaemia. Diabet Med. 2016 Feb;33(2):184-91
Sep 25, 2020
Autor: Roberto Luís Zagury
Ref: Branched-chain amino acids in metabolic signaling and insulin resistance. Nat Rev Endocrinol. 2014 Dec;10(12):723-36